Neurological disorders are major causes of morbidity and mortality worldwide. Disorders of the nervous system always attract the attention of researchers to search for novel and effective therapeutic strategies. Neurological disorders involve a complex cascade of events including oxidative and nitrosative stress leading to neuronal cell death. Several types of molecular mediators involved in disease progression and neuroprotection have been recognized as therapeutic targets. Researchers are continuously working to identify the inhibitors/activators that can modulate the pathophysiological pathway to halt the disease progression.

However, the critical issue of the non-recognized underlying etiology of neurological disorders still persists, which attracts the attention of researchers to explore the neuroprotective mechanism of drug-like candidates.

This Special Issue aims to present significant evidence of the potential of neurotherapeutic agents in neurological disorders including amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease, ischemic stroke, hemorrhagic stroke, traumatic brain injury (TBI), epilepsy and seizures, and spinal cord injury. This Special Issue welcomes original research and review papers focused on the use of synthetic compounds, phytochemicals, endogenous molecules, and biologics in improving neurological dysfunctions in preclinical and clinical studies. We encourage research studies carried out using in vivo rodent and nonrodent models to explore the mechanism of action and interaction of therapeutics compounds with molecular mediators of oxidative/nitrosative stress. Rather than only in vitro experiments or in silico work, we will consider research that includes a combination of in vitro/in silico and in vivo applications to models of neurological disorders.

Potential topics include but are not limited to the following:

• Neuroplasticity and neuroregeneration mechanisms of therapeutics in neurodegenerative model
• Targeting nNOS, iNOS, PARP-1, Calpain, Caspase, MMPs, AIF for neuroprotection
• Identification of novel therapeutic agents and evaluation of their neuroprotective potential using in vivo or in vitro models
• Evaluation of the neurotherapeutic potential of phytochemicals, peptides, and hormones
• Activation/inhibition mechanism of molecular mediators of neurological disorders
• Modulation of signaling pathways of oxidative/nitrosative stress in neurodegenerative disorders
• Role of neuroprotective agents in the modulation of apoptosis, necrosis, necroptosis, and autophagy
• Development of nanoformulations to mitigate oxidative stress and neurodegeneration
• Evaluation of the neuroprotective potential of antioxidant vitamins & synthetic compounds
• Modulation of oxidative stress molecular mediators of neurological disorders